A composition for aiding in the control of body fat and uses thereof

Abstract

This invention discloses a composition that helps control body fat and its applications, relating to the field of biotechnology. The composition comprises hesperidin and *Lactobacillus Johnsonii*. Research in this invention has found that this composition can synergistically upregulate the gene and protein expression of PGC1α and UCP1 in adipose tissue and increase body surface temperature; it can also significantly improve the bioavailability of hesperidin and increase the concentration of metabolites such as hesperidin in serum; it can also optimize the intestinal microecology, improve the intestinal flora structure, increase the colonization rate of *Lactobacillus*, enrich the abundance of beneficial bacteria, and promote the production of short-chain fatty acids; and it can also significantly improve lipid metabolism disorders, reduce fat accumulation, regulate adiponectin and leptin levels, control body fat, and achieve effective weight loss management.

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to a composition that helps control body fat and its application. Background Technology

[0002] In recent years, activating thermogenesis pathways in adipose tissue (such as inducing the expression of the uncoupling protein UCP1 in white adipose tissue) has become a novel strategy for the intervention of various metabolic syndromes. In the mitochondria of thermogenic adipose tissue, the electron transport chain is uncoupled from the ATP synthesis pathway to generate heat. UCP1 mediates the passage of protons across the inner mitochondrial membrane, dissipating protons (H... + Thermodynamics generates heat through a gradient. By activating the expression of thermogenic genes and proteins such as UCP1, it is possible to reduce body fat and combat obesity and metabolic syndrome. However, the development of drugs to promote the activation of brown adipose tissue and the browning of white adipose tissue has not made substantial progress. Existing technologies mainly activate thermodynamic pathways through the following pathways: ① Cold exposure or exercise: activating brown adipose tissue or inducing beige adipose tissue production through the sympathetic nervous system, but this is difficult to implement and has low compliance. ② Drug-targeted activation: such as β3-adrenergic receptor agonists, but there are risks such as inducing cardiovascular disease. ③ Such as capsaicin and resveratrol, which have low bioavailability and require high doses (>100 mg / kg), limiting their practical application. ④ Probiotic intervention: Some strains (such as Bifidobacterium animalis) can slightly increase UCP1 expression, but the efficiency is limited and they are difficult to colonize in the intestine.

[0003] Furthermore, current research in this field has the following limitations: ① Poor efficacy of single components: Numerous studies have shown that hesperidin, one of the most abundant flavonoids in citrus fruits, has minimal activation effect on thermogenic pathways, possibly due to its low bioavailability; while the effect of Lactobacillus johnsonii alone on regulating host thermogenic pathways is unknown, and it needs to overcome problems such as easy loss of activity and difficulty in intestinal colonization. ② Lack of synergy in combination regimens: Probiotics that have not undergone specific screening have low metabolic conversion efficiency, and simple combinations of probiotics and flavonoids do not show a synergistic effect on improving health. ③ Unclear mechanisms: Current technologies cannot achieve efficient expression of UCP1 protein and significant increase in core body temperature, and there is a lack of evidence for synergistic activation of thermogenics through strain-specific metabolic conversion (such as the hesperidin → hesperidin → UCP1 axis).

[0004] Based on the three major technical bottlenecks that urgently need to be addressed, this invention aims to develop a synergistic composition to improve the bioavailability of hesperidin and synergistically enhance the expression of key thermogenic genes and proteins, providing a novel solution for strategies to improve metabolic health by targeting the "gut microbiota-host metabolic axis". Summary of the Invention

[0005] The purpose of this invention is to provide a composition and its application that help control body fat, thereby addressing the problems existing in the prior art. The composition provided by this invention activates thermogenesis pathways through a "microbiota-host metabolic axis" linkage mechanism, thereby controlling body fat and achieving a synergistic improvement in metabolic health.

[0006] To achieve the above objectives, the present invention provides the following solution:

[0007] This invention provides a composition that helps control body fat, comprising hesperidin and Lactobacillus johnsonii (…). Lactobacillus Johnsonii ).

[0008] Furthermore, the ratio of hesperidin to Lactobacillus johnsonii is (20-30) mg: 1 × 10⁻⁶ mg. 9 CFU.

[0009] Preferably, the ratio of hesperidin to Lactobacillus johnsonii is 25 mg: 1 × 10⁻⁶. 9 CFU.

[0010] The present invention also provides the use of the above-described composition in the preparation of a product that helps control body fat, said product being a health food.

[0011] The present invention also provides a medicine that helps control body fat, the active ingredient of which includes the above-described composition.

[0012] Furthermore, the drug also includes pharmaceutically acceptable excipients.

[0013] Furthermore, the dosage form of the drug includes oral liquid, granules, tablets, capsules, pills, or powder.

[0014] The present invention also provides a health food that helps control body fat, the active ingredients of which include the above-described composition.

[0015] Furthermore, the health food also includes food additives.

[0016] Furthermore, the dosage form of the health food is oral liquid, granules, capsules, powder, or tablets.

[0017] The present invention discloses the following technical effects:

[0018] The composition provided by this invention activates thermogenesis pathways through a "microbiota-host metabolic axis" linkage mechanism, thereby controlling body fat and achieving the goal of synergistically improving the body's metabolic health. Specifically, the composition can synergistically upregulate the gene and protein expression of PGC1α and UCP1 in adipose tissue and increase body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and increase the concentration of metabolites such as hesperidin in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the colonization rate of lactobacilli, enrich the abundance of beneficial bacteria, and promote the production of short-chain fatty acids; the composition can also significantly improve the body's lipid metabolism disorders, reduce fat accumulation, regulate adiponectin and leptin levels, control body fat, and achieve effective weight loss management. Attached Figure Description

[0019] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0020] Figure 1 The images show the results of infrared thermography of the body surface and the detection of expression levels of heat-related genes and proteins (PGC1α, UCP1); where a is a representative image of in vitro infrared thermography; b is a statistical graph of the average core body temperature of each group; c and d are statistical graphs of gene expression levels of PGC1α and UCP1 in inguinal white adipose tissue iWAT, respectively; e is a Western blot analysis result of PGC1α and UCP1 in iWAT; f and g are statistical graphs of protein expression levels of PGC1α and UCP1, respectively.

[0021] Figure 2 This is a serum non-targeted metabolomics analysis of hesperetin metabolites; where a is the abundance of hesperetin in the serum of mice in each group; b is the abundance of hesperetin-3'-O-sulfate.

[0022] Figure 3 The graph shows the detection results of the effects of the composition of the present invention on the intestinal flora structure and the abundance of Lactobacillus; wherein, a is the PCA analysis graph of the intestinal flora structure; b is the graph of the relative proportion of Lactobacillus; and c is the graph of the analysis results of the differences between the groups.

[0023] Figure 4The following are the detection results of the effects of the composition of the present invention on liver fat accumulation and adipocyte size; wherein, a is the Oil Red O staining image of liver sections; b is the fat accumulation percentage analyzed based on the Oil Red O staining of the liver; c is the H&E staining result of white fat sections from the groin; d is the average adipocyte size determined based on the H&E staining analysis.

[0024] Figure 5 The graphs show the results of serum adiponectin / leptin levels and fecal SCFA content in each experimental group; where a and b are statistical graphs of serum adiponectin and leptin levels, respectively; ci are statistical graphs of total SCFA, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid and isovaleric acid content in feces.

[0025] Figure 6 The graphs show the results of weight management parameters for each experimental group; where a is a curve of weight change for the model group, hesperidin group, Lactobacillus johnsonii group, and the hesperidin-Lactobacillus johnsonii combined treatment group; b is a statistical graph of the final weight growth rate for the model group, hesperidin group, Lactobacillus johnsonii group, and the hesperidin-Lactobacillus johnsonii combined treatment group; c is a curve of weight change for the model group, hesperidin group, Lactobacillus reuteri group, and the hesperidin-Lactobacillus reuteri combined treatment group; and d is a statistical graph of the final weight growth rate for the model group, hesperidin group, Lactobacillus reuteri group, and the hesperidin-Lactobacillus reuteri combined treatment group. Detailed Implementation

[0026] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0027] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0028] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0029] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0030] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0031] The following examples use Lactobacillus johnsonii ( Lactobacillus Johnsonii ) and Lactobacillus reuteri ( Lactobacillus reuteri Both strains were purchased from the Guangdong Provincial Microbial Culture Collection Center (GDMCC), with strain numbers GDMCC 1.730 and GDMCC 1.614, respectively.

[0032] The hesperidin referred to in this invention has CAS number 520-26-3 and molecular formula C. 28 H 34 O 15 The structural formula is as follows:

[0033] .

[0034] Example 1: Effect of the composition of the present invention on the body's heat production capacity

[0035] (1) Grouping and Intervention

[0036] Forty 6-8 week old C57 / BL6J mice were randomly divided into four groups of 10 each. The groups were: model group (HFD), hesperidin group (HEP), Lactobacillus johnsonii group (LJ), and hesperidin-Lactobacillus johnsonii combined treatment group (HEP-LJ).

[0037] Each group of mice received a different intervention:

[0038] The model group mice were fed a high-fat diet (purified form with 60% fat as the energy source) and were given 0.2 mL of PBS solution by gavage daily.

[0039] Mice in the hesperidin group were given a high-fat diet containing 0.5% hesperidin and were given 0.2 mL of PBS solution by gavage daily.

[0040] Mice in the Lactobacillus johnsonii group were fed a high-fat diet and administered 0.2 mL of a solution containing 5 × 10⁻⁶ bacteria daily by gavage. 9 CFU / mL Lactobacillus johnsonii bacterial suspension;

[0041] Mice in the hesperidin-Lactobacillus johnsonii combined treatment group were given a high-fat diet containing 0.5% hesperidin and were administered 0.2 mL of a diet containing 5 × 10⁻⁶ Lactobacillus johnsonii via gavage daily. 9 CFU / mL Lactobacillus johnsonii bacterial suspension.

[0042] Mice consume approximately 5g of food daily, which translates to a daily intake of approximately 25mg of hesperidin. Therefore, the composition ratio used in this example is 1mg:4×10 7 CFU (hesperidin: Lactobacillus johnsonii). Mice in each group had free access to food and water. The temperature in the housing was 20-26℃, the relative humidity was 40-70%, the noise level was less than 60dB, and the photocycle was a 12h light and 12h dark cycle.

[0043] (2) Indicator detection

[0044] Mice in each group were fed according to their grouping and intervention methods for 6 weeks. On the last day of the experiment, the mice's body temperature was measured and images were acquired using an infrared thermal imager. Blood was collected from the mice after anesthesia, and inguinal beige adipose tissue (iWAT) was collected. Total RNA and protein were extracted from the iWAT and analyzed by qPCR and Western blotting to determine the gene and protein expression levels of PGC1α and UCP1.

[0045] (3) Experimental results

[0046] Infrared thermography, combined with the detection of key genes and proteins, can visually reflect the activation status of thermogenesis pathways in mice under different interventions. The results are as follows: Figure 1 As shown. After 6 weeks of different interventions, only the HEP-LJ group showed a significant increase in body surface core temperature, which was about 1°C higher than other groups. In addition, the gene expression and protein expression of PGC1α and UCP1 in the inguinal white adipose tissue of the HEP-LJ group mice were significantly upregulated (2-3 times), and significantly higher than those in the HFD group, HEP group and LJ group.

[0047] The results showed that hesperidin and Lactobacillus johnsonii had a synergistic effect in activating the body's thermogenic activity.

[0048] Example 2: Effect of the composition of the present invention on the bioavailability of hesperidin

[0049] (1) Grouping and Intervention

[0050] The group settings and intervention methods are the same as in Example 1.

[0051] (2) Indicator detection

[0052] Mice in each group were fed according to their grouping and intervention methods for 6 weeks. On the last day of the experiment, mice in each group were fasted but allowed free access to water for 10 hours. Blood was collected from mice after anesthesia, and serum was obtained after centrifugation for non-targeted metabolomics analysis of hesperidin metabolites.

[0053] (3) Experimental results

[0054] The relative abundance of the main metabolites of hesperidin in the serum of different groups of mice is as follows: Figure 2 As shown, hesperidin and its conjugates are the main metabolites. Due to the low bioavailability of hesperidin, the content of its metabolites in the serum of HEP group mice is not high. However, LJ supplementation accelerates the metabolism of hesperidin and improves its bioavailability. Specifically, the abundance of hesperidin and hesperidin-3'-O-sulfate in the serum of HEP-LJ group mice is significantly increased, by approximately 5 times and 2.7 times respectively compared with the HEP group.

[0055] Example 3: Effect of the composition of the present invention on the composition of gut microbiota

[0056] (1) Grouping and Intervention

[0057] The group settings and intervention methods are the same as in Example 1.

[0058] (2) Indicator detection

[0059] Mice in each group were fed according to their grouping and intervention methods for 6 weeks. On the last day of the experiment, mouse feces were collected for 16S rDNA sequencing to analyze the composition and abundance of gut microbiota.

[0060] (3) Experimental results

[0061] like Figure 3 As shown, the combined intervention of HEP-LJ significantly improved the structure of the gut microbiota, and its effect differed from that of the HFD group, HEP group, and LJ group. Compared with the HEP group and LJ group, the combined intervention of HEP-LJ significantly increased the abundance of Lactobacillus, exhibiting a synergistic proliferative effect. Furthermore, the combined intervention of HEP-LJ also promoted the growth of other beneficial bacteria, such as Lactobacillus synergists (…). Ligilactobacillus ).

[0062] The above results indicate that the composition of the present invention has a significant regulatory effect on promoting the colonization and proliferation of beneficial bacteria such as Lactobacillus and optimizing the intestinal flora structure.

[0063] Example 4: Effects of the composition of the present invention on liver and adipose tissue

[0064] (1) Grouping and Intervention

[0065] The group settings and intervention methods are the same as in Example 1.

[0066] (2) Indicator detection

[0067] On the last day of the experiment, mice in each group were fasted for 10 hours but allowed free access to water. Mice were anesthetized and dissected, and adipose tissue and liver were collected. The liver was fixed in 4% paraformaldehyde, sectioned, and stained with Oil Red O; the inguinal white adipose tissue (iWAT) was fixed, sectioned, and stained with H&E.

[0068] (3) Experimental results

[0069] The effects of HEP-LJ combined intervention on hepatic fat accumulation and adipose tissue size, such as Figure 4 As shown in the figure. The results indicate that the combined HEP-LJ intervention significantly reduced fat accumulation in the liver, with the Oil Red O staining area decreasing by approximately 40% compared to the model group. The combined HEP-LJ intervention also significantly reduced the size of inguinal white adipocytes, exhibiting a synergistic improvement effect compared to HEP and LJ interventions alone.

[0070] Example 5: Effects of the composition of the present invention on serum adipokines and intestinal short-chain fatty acids

[0071] (1) Grouping and Intervention

[0072] The group settings and intervention methods are the same as in Example 1.

[0073] (2) Indicator detection

[0074] On the last day of the experiment, mice in each group were fasted for 10 hours but allowed free access to water. Mice were anesthetized and dissected, and adipose tissue and liver were collected. The liver was fixed in 4% paraformaldehyde, sectioned, and stained with Oil Red O; the inguinal white adipose tissue (iWAT) was fixed, sectioned, and stained with H&E.

[0075] (3) Experimental results

[0076] Obesity caused by a high-fat diet usually leads to leptin resistance, decreased adiponectin levels, and decreased levels of short-chain fatty acids in the gut. Figure 5 The results showed that HEP-LJ combined intervention alone significantly increased adiponectin levels and decreased leptin levels. Furthermore, HEP-LJ combined intervention also significantly increased the content of short-chain fatty acids in feces, particularly in promoting the production of total short-chain fatty acids, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid.

[0077] Example 6: Effects of the composition of the present invention and the comparative composition on weight management

[0078] Experimental grouping: Sixty 6-8 week old C57 / BL6J mice were randomly divided into 6 groups, with 10 mice in each group. The groups were: model group (HFD), hesperidin group (HEP), Lactobacillus johnsonii group (LJ), hesperidin-Lactobacillus johnsonii combined treatment group (HEP-LJ), Lactobacillus reuteri group (LR), and hesperidin-Lactobacillus reuteri combined treatment group (HEP-LR).

[0079] Each group of mice received a different intervention:

[0080] The model group mice were fed a high-fat diet and were given 0.2 mL of PBS solution by gavage daily;

[0081] Mice in the hesperidin group were given a high-fat diet containing 0.5% hesperidin and were given 0.2 mL of PBS solution by gavage daily.

[0082] Mice in the Lactobacillus johnsonii group were fed a high-fat diet and administered 0.2 mL of a solution containing 5 × 10⁻⁶ bacteria daily by gavage. 9 CFU / mL Lactobacillus johnsonii bacterial suspension;

[0083] Mice in the hesperidin-Lactobacillus johnsonii combined treatment group were given a high-fat diet containing 0.5% hesperidin and were administered 0.2 mL of a diet containing 5 × 10⁻⁶ Lactobacillus johnsonii via gavage daily. 9 CFU / mL Lactobacillus johnsonii bacterial suspension;

[0084] Mice in the Lactobacillus reuteri group were given a high-fat diet and administered 0.2 mL of a solution containing 5 × 10⁻⁶ bacteria daily by gavage. 9 CFU / mL Lactobacillus reuteri bacterial suspension;

[0085] Mice in the hesperidin-Lactobacillus reuteri combined treatment group were given a high-fat diet containing 0.5% hesperidin and were administered 0.2 mL of a diet containing 5 × 10⁻⁶ Lactobacillus daily by gavage. 9 CFU / mL Lactobacillus reuteri bacterial suspension.

[0086] Mice consumed approximately 5g of food per day, which translates to a daily intake of approximately 25mg of hesperidin. Mice in each group had free access to food and water. The housing temperature was 20-26℃, relative humidity 40-70%, noise level less than 60dB, and the photocycle consisted of a 12-hour light cycle followed by a 12-hour dark cycle.

[0087] Indicator detection and results: Mice in each group were fed according to their grouping and intervention methods for 6 weeks, and their body weight was measured weekly. Results are as follows: Figure 6 As shown, the group treated with Lactobacillus johnsonii in combination with hesperidin (HEP-LJ) experienced a significant reduction in body weight, with a stronger effect than the single-action groups. However, at the same dosage, the group treated with Lactobacillus reuteri in combination with hesperidin (HEP-LR) did not show a synergistic effect in weight management.

[0088] The results of this study indicate that the synergistic effect of weight management is unique to Lactobacillus johnsonii and hesperidin.

[0089] Example 7: Application of the composition of the present invention in oral liquid

[0090] A method for preparing an oral liquid that helps control body fat:

[0091] (1) Bacterial culture: Lactobacillus johnsonii was inoculated into MRS liquid medium and cultured anaerobically at 37°C for 48 hours.

[0092] (2) Collection of bacterial cells: After centrifugation (4℃, 6000×g, 10min), the supernatant was discarded and the bacterial cells were resuspended in phosphate buffer at pH 5.0. The bacterial suspension was centrifuged again (4℃, 6000×g, 10min) to remove residual culture medium. The bacterial cells were then resuspended in phosphate buffer at pH 5.0 (containing 10% food-grade trehalose) to obtain the bacterial suspension mother liquor.

[0093] (3) Compound preparation: Hesperidin (food grade, purity ≥98%) naturally extracted from orange peel is mixed with the bacterial suspension, and the viable count is adjusted to 10. 9 The solution contains CFU / mL and hesperidin at a concentration of 25 mg / mL, and is formulated as an oral liquid.

[0094] (4) Packaging: After standardized production, the prepared oral liquid is aseptically packaged into individual small packages and labeled with product labels.

[0095] (5) Quality control: After serial dilution, an appropriate amount of oral liquid was spread on MRS agar plates and incubated in an anaerobic environment at 37°C for 48 hours. The total number of viable bacteria in the oral liquid was calculated. The viable bacteria decay kinetics at different storage temperatures were detected to verify the stability of the oral liquid. An appropriate amount of oral liquid was extracted with methanol-DMSO solution and analyzed by high performance liquid chromatography (C18 column, methanol-0.1% formic acid-water gradient elution method, detection wavelength 283 nm). The actual hesperidin content in the oral liquid was calculated based on the curves of different concentration standards.

[0096] Example 8

[0097] Same as Example 7, except that in step (3), the content of hesperidin in the oral liquid is adjusted to 20 mg / mL.

[0098] Example 9

[0099] Same as Example 7, except that in step (3), the content of hesperidin in the oral liquid is adjusted to 30 mg / mL.

[0100] Example 10: Application of the composition of the present invention in capsules

[0101] (1) Bacterial culture: Lactobacillus johnsonii was inoculated into MRS liquid medium and cultured anaerobically at 37°C for 48 hours.

[0102] (2) Collection of bacterial cells: After centrifugation (4℃, 6000×g, 10min), the supernatant was discarded and the bacterial cells were resuspended in phosphate buffer at pH 5.0; after centrifugation again (4℃, 6000×g, 10min), the residual culture medium was removed and the bacterial cells were resuspended in phosphate buffer at pH 5.0 (containing 10% skim milk and 5% trehalose) to obtain the bacterial suspension mother liquor.

[0103] (3) Freeze-drying of bacterial cells: The bacterial suspension is freeze-dried to obtain freeze-dried Lactobacillus johnsonii powder.

[0104] (4) Detection of bacterial survival rate: Take an appropriate amount of freeze-dried powder to prepare a bacterial suspension, dilute it in a gradient, spread it on MRS agar medium plates, and incubate it in an anaerobic environment at 37℃ for 48 hours. Measure the total number of live bacteria in the freeze-dried powder and calculate the freeze-dried survival rate.

[0105] (5) Mixing and filling: Hesperidin was subjected to ultrafine grinding to obtain hesperidin micro powder with a particle size ≤50μm; it was mixed with freeze-dried bacterial powder and filled into hydroxypropyl methylcellulose enteric-coated capsules, controlling the content of hesperidin to 25mg and live bacteria to 10mg per capsule. 9 CFU).

[0106] (6) Packaging: The filled capsules are aseptically repackaged into individual small packages and labeled with product labels.

[0107] (7) Quality control: Take an appropriate amount of capsule contents to prepare a suspension, dilute it serially, spread it on MRS agar plates, and incubate it in an anaerobic environment at 37℃ for 48 hours. Calculate the total number of viable bacteria in the capsules. Take an appropriate amount of the suspension, extract it with methanol-DMSO solution, and analyze it using high performance liquid chromatography (C18 column, methanol-0.1% formic acid-water gradient elution method, detection wavelength 283nm). Calculate the actual hesperidin content in the capsules based on the standard curves of different concentrations.

[0108] Example 11

[0109] Same as Example 10, except that in step (5), the hesperidin content in each capsule is adjusted to 20 mg.

[0110] Example 12

[0111] Same as Example 10, except that in step (5), the hesperidin content in each capsule is adjusted to 30 mg.

[0112] Example 13 Application of the composition of the present invention in functional solid beverages

[0113] (1) Formulation composition: By weight, this formulation contains 8 parts of the compound powder (containing 40 mg / g hesperidin + 2 × 10 parts of lyophilized Lactobacillus johnsonii powder). 9 (CFU / g), 65 parts maltodextrin, 15 parts resistant dextrin, 10 parts natural orange powder and 2 parts sucralose.

[0114] (2) Preparation process: Hesperidin micro powder and Lactobacillus johnsonii lyophilized powder were prepared according to the method of Example 10, and thoroughly mixed at a mass ratio of 1:50 to obtain a composite powder (containing 40 mg / g hesperidin + 2 × 10 g Lactobacillus johnsonii lyophilized powder). 9 (CFU / g); the compound powder and the prescribed amounts of maltodextrin and resistant dextrin are put into a V-type mixer and mixed thoroughly at 15 rpm for 15 minutes; after the mixed powder is passed through an 80-mesh sieve, the prescribed amounts of natural orange powder and sucralose are added for flavoring, and then put into the mixer again for a second mixing; after thorough mixing, it is packaged in aluminum foil bags, 10g per bag, and sealed with nitrogen gas.

[0115] (3) Quality control: The detection of viable bacteria count and hesperidin content were the same as in Example 10.

[0116] Example 14

[0117] Same as Example 13, except that the hesperidin content in the powdered composition is adjusted to 50 mg / g.

[0118] Example 15

[0119] Same as Example 13, except that the hesperidin content in the powdered composition is adjusted to 60 mg / g.

[0120] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A composition that helps control body fat, characterized in that, Including hesperidin and Lactobacillus johnsonii ( Lactobacillus Johnsonii ); The strain number of the Lactobacillus johnsonii is GDMCC 1.

730.

2. The composition according to claim 1, characterized in that, The ratio of the hesperidin and the L. johnsonii is (20-30) mg: 1 x 10 9 CFU.

3. The composition according to claim 2, characterized in that, The ratio of hesperidin to Lactobacillus johnsonii is 25 mg: 1 × 10⁻⁶. 9 CFU.

4. The use of the composition according to any one of claims 1-3 in the preparation of a product that helps control body fat, characterized in that, The product in question is a health food product.

5. A drug that helps control body fat, characterized in that, The active ingredient includes the composition according to any one of claims 1-3.

6. The drug according to claim 5, characterized in that, The drug also includes pharmaceutically acceptable excipients.

7. The drug according to claim 6, characterized in that, The dosage forms of the drug include oral liquid, granules, tablets, capsules, pills, or powder.

8. A health food product that helps control body fat, characterized in that, The active ingredient includes the composition according to any one of claims 1-3.

9. The health food according to claim 8, characterized in that, The health food products also include food additives.

10. The health food according to claim 9, characterized in that, The dosage form of the health food is oral liquid, granules, capsules, powder or tablets.

Images